Skip to main content

Market Overview

EMA's Medicinal Committee Backs Eli Lilly's COVID-19 Antibody Therapy

Share:
  • European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly and Co's (NYSE: LLY) bamlanivimab alone, and bamlanivimab plus etesevimab, in COVID-19 in patients.
  • The opinion covers the COVID-19 antibody therapy for patients aged 12 years and older who do not require supplemental oxygen and are at high risk of progressing to severe COVID-19.
  • In February, the antibody therapy received FDA Emergency Use Approval.
  • Recently, the U.S. government agreed to purchase a minimum of 100,000 doses of antibody therapy, in an agreement valued at $210 million.
  • Price Action: LLY shares increased 1.9% at $204.32 in market trading hours on the last check Friday.
 

Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: CHMP Covid-19Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com